Glenmark starts Revamilast Phase IIb trials – Pharmaceutical Business Review


Moneycontrol.com

Glenmark starts Revamilast Phase IIb trials
Pharmaceutical Business Review
Indian drug maker Glenmark Pharmaceuticals has started Phase IIb trials to evaluate Revamilast (GRC 4039) as a treatment for inflammatory disorders like rheumatoid arthritis (RA) and asthma. The trials aim to determine the safety and efficacy profile
Glenmark starts Phase-IIb human trials of Revamilast moleculeEconomic Times
Glenmark starts phase IIb human trials of moleculemydigitalfc.com
Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule PR Newswire (press release)

all 30 news articles »

View full post on asthma – Google News

Glenmark starts Phase-IIb human trials of Revamilast molecule – Economic Times

Glenmark starts Phase-IIb human trials of Revamilast molecule
Economic Times
NEW DELHI: Glenmark Pharmaceuticals on Wednesday said it has started Phase-IIb human trials of its 'Revamilast' molecule, which is being developed for treatment of inflammatory disorders like asthma and rheumatoid arthritis. The Phase-IIb studies of
Glenmark initiates Phase IIb human trials globally for its novel molecule India Infoline.com

all 7 news articles »

View full post on asthma – Google News